Загрузка...
A Phase I Trial of Escalating Doses of Cixutumumab (IMC- A12) and Sorafenib in the Treatment of Advanced Hepatocellular Carcinoma
PURPOSE: The insulin-like growth factor (IGF) pathway is activated in hepatocarcinogenesis. Cixutumumab is a monoclonal antibody against human insulin-like growth factor-1 receptor (IGF-1R). Given the cross-talk between the IGF and VEGF pathways, we performed a phase I study of the combination of ci...
Сохранить в:
| Опубликовано в: : | Cancer Chemother Pharmacol |
|---|---|
| Главные авторы: | , , , , , , , , , , , |
| Формат: | Artigo |
| Язык: | Inglês |
| Опубликовано: |
2018
|
| Предметы: | |
| Online-ссылка: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6330274/ https://ncbi.nlm.nih.gov/pubmed/29520435 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s00280-018-3553-4 |
| Метки: |
Добавить метку
Нет меток, Требуется 1-ая метка записи!
|